Octagam 1gm/20ml Inj, 1 Vial

• Live virus vaccines (e.g., measles, mumps, rubella, varicella) - due to potential interference with vaccine efficacy. Delay vaccination for at least 3 months (up to 1 year for measles) after IVIG administration.

• Live virus vaccines (e.g., measles, mumps, rubella, varicella)

• Loop diuretics (e.g., furosemide) - increased risk of acute renal dysfunction, especially in predisposed patients.
• Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) - increased risk of acute renal dysfunction when co-administered with IVIG, particularly in patients with risk factors.

• Headache
• Chills
• Fever
• Nausea
• Vomiting
• Rash
• Hives
• Chest pain
• Shortness of breath (dyspnea)
• Wheezing
• Swelling of face, lips, tongue, or throat (signs of anaphylaxis)
• Pain, swelling, warmth, or redness in an arm or leg (signs of thrombosis)
• Sudden numbness or weakness on one side of the body (signs of stroke)
• Sudden severe headache
• Changes in vision
• Dark urine
• Decreased urine output
• Unusual tiredness or weakness

Category C. Animal reproduction studies have not been conducted. It is not known whether Octagam can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Octagam should be given to a pregnant woman only if clearly needed. However, IVIG is often used in pregnancy for certain autoimmune conditions (e.g., ITP, recurrent pregnancy loss) where the benefits outweigh potential risks.

L3 (Moderately Safe). Human IgG is excreted into breast milk and may contribute to the transfer of protective antibodies to the neonate. No adverse effects on the breastfed infant are expected. Consider the benefits of breastfeeding along with the mother's clinical need for Octagam and any potential adverse effects on the breastfed infant from Octagam or the underlying maternal condition.

Dosing is weight-based and indication-specific. Safety and efficacy have been established for various pediatric indications (e.g., PI, ITP, Kawasaki disease). Infusion rates should be carefully monitored, especially in younger children and those with underlying cardiac or renal conditions, to minimize the risk of adverse reactions.

Patients >65 years of age are at increased risk for acute renal dysfunction and thrombotic events. Administer at the minimum dose and infusion rate practicable. Ensure adequate hydration. Monitor renal function and for signs/symptoms of thrombosis closely.

• Always ensure adequate hydration before, during, and after infusion to minimize the risk of renal dysfunction and thrombosis.
• Start infusion at a slow rate and gradually increase if tolerated, especially for the first infusion or in patients at risk for adverse reactions.
• Pre-medication (e.g., antihistamines, acetaminophen) may be considered for patients with a history of infusion-related reactions.
• Screen patients for IgA deficiency prior to the first infusion. Patients with severe IgA deficiency and antibodies to IgA are at increased risk of anaphylaxis.
• Monitor vital signs closely throughout the infusion and for a period afterward.
• Be vigilant for signs of thrombosis (e.g., localized pain, swelling, neurological deficits) and renal dysfunction (e.g., decreased urine output, elevated creatinine).
• Educate patients about the importance of reporting any adverse symptoms promptly.

• Other IVIG products (different brands/manufacturers)
• Subcutaneous Immune Globulin (SCIG) for primary immunodeficiencies
• Corticosteroids (e.g., prednisone) for autoimmune conditions like ITP, CIDP
• Other immunosuppressants (e.g., rituximab, azathioprine, mycophenolate mofetil) for autoimmune conditions
• Plasma exchange (plasmapheresis) for certain neurological conditions (e.g., GBS, CIDP)